1%) produced biofilm, of which one third (38
It is intrinsically resistant to many antibiotics and has the ability to acquire antibiotic resistance by multiple mechanisms
It is an uncommon bacterium and human infection is difficult to treat
maltophilia bacteremia in hospitalized adults at our institution to determine the population at risk, sources of infection, common complications, antimicrobial susceptibility May 15, 2023 · 1
Environmental and clinical isolates often exhibit multiple antibiotic resistance
In scenarios where minocycline has been used for treatment, the most common dose is 100 mg twice daily, often with an initial 200 mg loading dose
The treatment of infection caused by S
Stenotrophomonas maltophilia keratitis is an uncommon infectious disease of the cornea
Ceftazidime and ticarcillin/clavulanate were previously the most effective β-lactam drugs against S
Background: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high
S
Determining breakpoints in the face of poorly standardised methodology and few clinical data to support decisions is almost impossible
We evaluated the in vitro activity and reproducibility of two different super-position methods of aztreonam in combination with ceftazidime-avibactam for S
Risk factors associated with S
Stenotrophomonas maltophilia is a gram-negative, multidrug-resistant organism that is typically hospital-acquired and associated with high morbidity and mortality [1, 2]
Stenotrophomonas maltophilia is naturally resistant to many antimicrobials
Stenotrophomonas maltophilia is an emerging nosocomial pathogen in immunocompromised patients [1-3]
Stenotrophomonas maltophilia is a multidrug-resistant bacterium that can cause serious eye infections, such as endophthalmitis
Stenotrophomonas maltophilia is a ubiquitous soil bacterium that is increasingly recognized as an emerging nosocomial pathogen
maltophilia) is a gram-negative bacillus emerging as an opportunistic, nosocomial pathogen associated with a high mortality rate
In scenarios where minocycline has been used for treatment, the most common dose is 100 mg twice daily, often with an initial 200 mg loading dose
Introducción Stenotrophomonas maltophilia, ante-riormente conocida como Xanthomonas maltophilia y Pseudomonas maltophilia (1), es un bacilo Gram negativo, aeróbico, no fer-mentador de la glucosa, el cual ha sido aisla- Background
Fluoroquinolones have become a popular treatment option for Stenotrophomonas maltophilia infections
Stenotrophomonas maltophilia is a motile, aerobic, glucose non-fermenting, non-sporulating, Gram-negative bacillus ,
This guidance document provides recommendations to clinicians for treatment of infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P
8%, 1114/2330) were the most common source of isolates
Phenotypic susceptibility testing via commercial automated test systems is problematic and no Food and Drug Administration breakpoints are approved
a Antibiotic susceptibility of Stenotrophomonas maltophilia strains isolated from the respiratory tract samples (n = 282)
Stenotrophomonas maltophilia is an important multidrug-resistant nosocomial pathogen associated with high mortality
(Brooke, 2012) The characteristic low-susceptibility of this organism to different antibiotics mainly relies in the presence in its genome of genes encoding several intrinsic resistance elements that